S. de Jong

发表

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 2009, PLoS medicine.

Differential regulation of IL‐6 promoter activity in a human ovarian‐tumor cell line transfected with various p53 mutants: Involvement of AP‐1

E. D. de Vries, E. Vellenga, S. de Jong, 1999, International journal of cancer.

Molecular prognostic markers in ovarian cancer: toward patient‐tailored therapy

E. D. de Vries, S. de Jong, A. Crijns, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Profiling studies in ovarian cancer: a review.

A. V. D. Van Der Zee, E. D. de Vries, A. Crijns, 2007, The oncologist.

Sample preparation of human serum for the analysis of tumor markers. Comparison of different approaches for albumin and gamma-globulin depletion.

H. D. de Bruijn, A. V. D. Van Der Zee, S. de Jong, 2003, Journal of chromatography. A.

Detection of micrometastatic breast cancer by means of real time quantitative RT‐PCR and immunostaining in perioperative blood samples and sentinel nodes

E. D. de Vries, S. de Jong, J. Wesseling, 2003, International journal of cancer.

miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy

S. de Jong, L. Looijenga, M. V. van Vugt, 2019, Cells.

ENDOTOXIN INCREASES PLASMA SOLUBLE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND LEVEL MEDIATED BY THE p38 MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY

E. D. de Vries, S. de Jong, J. Zijlstra, 2004, Shock.

Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways

A. V. D. Van Der Zee, S. de Jong, G. Meersma, 2016, Genome Medicine.

Telomerase in relation to expression of p53, c-Myc and estrogen receptor in ovarian tumours.

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 2003, International journal of oncology.

Inhibition of IGF-1R-Dependent PI3K Activation Sensitizes Colon Cancer Cells Specifically to DR5-Mediated Apoptosis But Not to rhTRAIL

E. D. de Vries, S. de Jong, E. de Vries, 2010, Analytical cellular pathology.

Death Receptor Ligands, in Particular TRAIL, to Overcome Drug Resistance

E. D. de Vries, S. de Jong, T. Timmer, 2004, Cancer and Metastasis Reviews.

Targeting TRAIL death receptors.

E. D. de Vries, S. de Jong, A. Walenkamp, 2008, Current opinion in pharmacology.

The clinical trail of TRAIL.

E. D. de Vries, S. de Jong, J. Gietema, 2006, European journal of cancer.

The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis‐inducing stimuli

E. D. de Vries, E. Vellenga, D. Spierings, 2003, The Journal of pathology.

Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL*

S. de Jong, G. Montoya, W. Quax, 2012, Molecular & Cellular Proteomics.

H. Hollema, E. D. de Vries, S. de Jong, 2011, The Journal of pathology.

Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.

H. Boezen, H. Hollema, A. V. D. Van Der Zee, 2005, Gynecologic oncology.

Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 1994, Cancer research.

A biological question and a balanced (orthogonal) design: the ingredients to efficiently analyze two-color microarrays with Confirmatory Factor Analysis

A. V. D. Van Der Zee, E. D. de Vries, A. Crijns, 2006, BMC Genomics.

Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab

E. D. de Vries, S. de Jong, M. L. Lub-de Hooge, 2016, Oncotarget.

Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour.

S. de Jong, P. Jager, B. Rikhof, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer

H. Boezen, H. Hollema, A. V. D. Van Der Zee, 2010, British Journal of Cancer.

The role of apoptosis-related genes in non-small-cell lung cancer.

H. Groen, E. D. de Vries, S. de Jong, 2002, Clinical lung cancer.

The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer.

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 2010, Gynecologic oncology.

Effect of novobiocin on cisplatin cytotoxicity and dna interstrand cross‐link formation in a cisplatin‐resistant, small‐cell lung carcinoma cell line

S. de Jong, N. Mulder, E. de Vries, 1993, International journal of cancer.

Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic Vulnerabilities

S. de Jong, B. Bakker, B. Evers, 2022, International journal of molecular sciences.

Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers.

H. Groen, E. D. de Vries, S. de Jong, 2006, Lung cancer.

Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer.

E. D. de Vries, S. de Jong, A. V. D. van der Zee, 2012, Current cancer drug targets.

Robust metabolic transcriptional components in 34,494 patient-derived samples and cell lines

R. Fehrmann, S. de Jong, M. Walvoort, 2020, SSRN Electronic Journal.

P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 1991, Cancer research.

Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.

A. V. D. Van Der Zee, E. D. de Vries, S. de Jong, 2008, International journal of radiation oncology, biology, physics.

Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 2001, International journal of cancer.

Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1

S. de Jong, B. A. van Gorkom, E. de Vries, 2002, British Journal of Cancer.

Tissue Distribution of the Death Ligand TRAIL and Its Receptors

H. Hollema, E. D. de Vries, E. Vellenga, 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?

G. Peters, S. de Jong, F. Kruyt, 2013, Critical reviews in oncology/hematology.

Different type of DNA damage caused by three aziridinyl substituted cyclophosphazenes in a human small cell lung carcinoma cell line.

S. de Jong, N. Mulder, E. de Vries, 1986, Cancer research.

Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods

A. Zee, A. V. D. Van Der Zee, S. de Jong, 2015, Scientific Reports.

Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.

H. Hollema, H. Arts, E. D. de Vries, 2004, Gynecologic oncology.

Development of a radioiodinated apoptosis–inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies

E. D. de Vries, S. de Jong, J. Kosterink, 2012, British journal of pharmacology.

Translating TRAIL-receptor targeting agents to the clinic.

E. D. de Vries, S. de Jong, J. Gietema, 2013, Cancer letters.

Expression of TRAIL (TNF‐related apoptosis‐inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas

H. Hollema, E. D. de Vries, S. de Jong, 2003, The Journal of pathology.

The prognostic value of TRAIL and its death receptors in cervical cancer.

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 2009, International journal of radiation oncology, biology, physics.

Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy

S. de Jong, F. Kruyt, M. de Looff, 2019, Front. Immunol..

A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 2008, International journal of cancer.

Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas

H. Hollema, S. de Jong, E. de Vries, 2004, Histopathology.

Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy.

E. D. de Vries, S. de Jong, C. M. V. van Geelen, 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature.

S. de Jong, A. Karrenbeld, N. Zwart, 2003, European journal of gastroenterology & hepatology.

TRAIL-induces Src mediated MEK/ERK, SMAD3 and β-catenin signalling in apoptosis resistant NSCLC cells

S. de Jong, F. Kruyt, M. de Looff, 2022, bioRxiv.

Independent Induction of Caspase-8 and cFLIP Expression during Colorectal Carcinogenesis in Sporadic and HNPCC Adenomas and Carcinomas

S. de Jong, J. Wesseling, J. Kleibeuker, 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear.

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NMR spectroscopy analysis of phosphorus metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and -resistant human small cell lung carcinoma cell line.

S. de Jong, N. Mulder, E. de Vries, 1991, British Journal of Cancer.

Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells

E. D. de Vries, D. Spierings, S. de Jong, 2005, British Journal of Cancer.

Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.

S. de Jong, J. Wesseling, N. Zwart, 2014, Carcinogenesis.

Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.

H. Boezen, H. Boezen, H. Hollema, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1

E. D. de Vries, S. de Jong, M. van der Deen, 2007, British Journal of Cancer.

Fas Ligand Expression in Lynch Syndrome-Associated Colorectal Tumours

H. Hollema, E. D. de Vries, S. de Jong, 2008, Pathology & Oncology Research.

Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic.

H. Groen, E. D. de Vries, S. de Jong, 2007, Critical reviews in oncology/hematology.

Robust and independent metabolic transcriptional components in 34,494 patient-derived samples and cell lines: a resource for translational cancer research

R. Fehrmann, S. de Jong, M. Walvoort, 2020, bioRxiv.

Detection of DNA cross‐links in tumor cells with the ethidium bromide fluorescence assay

S. de Jong, N. Mulder, E. de Vries, 1986, International journal of cancer.

Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.

S. de Jong, N. Mulder, E. de Vries, 1990, Cancer research.

Increased sensitivity of an adriamycin-resistant human small cell lung carcinoma cell line to mitochondrial inhibitors.

S. de Jong, N. Mulder, E. de Vries, 1992, Biochemical and biophysical research communications.

Erratum: Interrogating open issues in cancer medicine with patient-derived xenografts

Hans Clevers, Manuel Hidalgo, Eva Budinská, 2017, Nature Reviews Cancer.

Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours.

D. Spierings, S. de Jong, J. Gietema, 2005, The international journal of biochemistry & cell biology.

Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer

S. de Jong, M. V. van Vugt, J. Gietema, 2013, Expert Reviews in Molecular Medicine.

Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.

S. de Jong, R. Bischoff, J. Gibcus, 2010, The Journal of clinical investigation.

Disruption of the MDM2–p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway

S. de Jong, R. Bischoff, J. Gietema, 2011, Cell Death and Disease.

DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art

E. Schuuring, A. V. D. Van Der Zee, S. de Jong, 2012, Cellular Oncology.

Patient-derived xenograft models: an emerging platform for translational cancer research.

Manuel Hidalgo, Eva Budinská, Carlos Caldas, 2014, Cancer discovery.

The insulin‐like growth factor system and sarcomas

S. de Jong, B. Rikhof, A. Suurmeijer, 2009, The Journal of pathology.

Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer.

S. de Jong, J. Kleibeuker, F. Kruyt, 2010, Biochimica et Biophysica Acta.

Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

S. de Jong, G. Meersma, M. V. van Vugt, 2019, Molecular Cancer Therapeutics.

TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas

E. D. de Vries, S. de Jong, J. Wesseling, 2006, Clinical Cancer Research.

Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature.

H. Hollema, S. de Jong, E. de Vries, 2003, Critical reviews in oncology/hematology.

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.

A. V. D. Van Der Zee, K. Berns, S. de Jong, 2018, Biochimica et biophysica acta. Reviews on cancer.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma

R. Bernards, J. Brenton, A. V. D. Van Der Zee, 2018, Clinical Cancer Research.

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

E. D. de Vries, A. Crijns, S. de Jong, 2009, British Journal of Cancer.

Fas receptor‐mediated apoptosis: a clinical application?

S. de Jong, T. Timmer, E. D. de Vries, 2002, The Journal of pathology.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Yvonne A. Evrard, Michael W. Lloyd, Jeffrey H. Chuang, 2021, Nature Genetics.

Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models

S. de Jong, F. Giles, D. Mahalingam, 2019, Cancers.

Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL

S. de Jong, B. Rikhof, C. Meijer, 2008, British Journal of Cancer.

Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome.

E. D. de Vries, S. de Jong, R. Hofstra, 2011, Critical reviews in oncology/hematology.

Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.

S. de Jong, M. V. van Vugt, G. Wisman, 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy

E. D. de Vries, S. de Jong, A. Crijns, 2005, International Journal of Gynecologic Cancer.

IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.

R. Meijering, S. de Jong, A. Reyners, 2017, Cancer treatment reviews.

Kinome profiling of non-canonical TRAIL signaling reveals RIP1–Src–STAT3-dependent invasion in resistant non-small cell lung cancer cells

G. Peters, S. de Jong, W. Quax, 2012, Journal of Cell Science.

MiR‐17/106b seed family regulates p21 in Hodgkin's lymphoma

S. de Jong, A. van den Berg, B. Kroesen, 2011, The Journal of pathology.

TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives.

H. Groen, S. de Jong, E. de Vries, 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.

E. Schuuring, S. de Jong, G. Meersma, 2012, The American journal of pathology.

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer

M. Widschwendter, E. Schuuring, A. V. D. Van Der Zee, 2017, BMC Medicine.

Targeting TRAIL towards the clinic.

E. D. de Vries, S. de Jong, F. Giles, 2011, Current drug targets.

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

S. de Jong, D. Mahalingam, M. Keane, 2009, Cancer treatment reviews.

Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.

H. Groen, H. Boezen, E. D. de Vries, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities.

S. de Jong, M. V. van Vugt, G. de Vries, 2020, Cancer treatment reviews.

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.

R. Bernards, A. V. D. Van Der Zee, S. de Jong, 2019, Cancer letters.

The role of ATM and 53BP1 as predictive markers in cervical cancer

H. Hollema, E. Schuuring, A. V. D. Van Der Zee, 2012, International journal of cancer.

MEIS and PBX homeobox proteins in ovarian cancer.

H. Hollema, E. D. de Vries, D. Geerts, 2007, European journal of cancer.

Telomerase in (pre)neoplastic cervical disease.

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 2000, Human pathology.

MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1

E. Giovannetti, G. Peters, S. de Jong, 2013, Apoptosis.

Expression of proteins correlated with the unique cisplatin-sensitivity of testicular cancer.

S. de Jong, N. Mulder, E. de Vries, 1997, Anticancer research.

Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent

S. de Jong, E. de Vries, N. Mulder, 2012, Cell cycle.

Human Papilloma Virus 16 E6 RNA Interference Enhances Cisplatin and Death Receptor-Mediated Apoptosis in Human Cervical Carcinoma Cells

A. V. D. Van Der Zee, E. D. de Vries, S. de Jong, 2012, Molecular Pharmacology.

Proteasome inhibitor MG132 sensitizes HPV‐positive human cervical cancer cells to rhTRAIL‐induced apoptosis

S. de Jong, E. de Vries, J. Maduro, 2006, International journal of cancer.

Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid.

A. V. D. Van Der Zee, E. D. de Vries, S. de Jong, 2005, Gynecologic oncology.

Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance.

Elisabeth G E de Vries, A. V. D. Van Der Zee, E. D. de Vries, 2005, The Lancet. Oncology.

Avenues to molecular imaging of dying cells: Focus on cancer

S. de Jong, A. van Waarde, J. Gietema, 2018, Medicinal research reviews.

Metformin: taking away the candy for cancer?

Mathilde Jalving, Elisabeth G E de Vries, E. D. de Vries, 2010, European journal of cancer.

Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications

E. D. de Vries, S. de Jong, J. Gietema, 2006, Clinical Cancer Research.

Exploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run.

S. de Jong, E. D. de Vries, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.

E. D. de Vries, S. de Jong, L. Lancashire, 2008, Neoplasia.

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer

H. Hollema, E. D. de Vries, A. Crijns, 2008, British Journal of Cancer.

Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene

N. Rosenfeld, R. Bernards, M. Jimenez-Linan, 2020, PloS one.

JC Virus Infection in Colorectal Neoplasia That Develops after Liver Transplantation

M. Selgrad, C. Boland, L. Ricciardiello, 2008, Clinical Cancer Research.

MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

E. D. de Vries, R. Fehrmann, S. de Jong, 2019, The Journal of pathology.

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis

A. V. D. Van Der Zee, E. D. de Vries, S. de Jong, 2011, British Journal of Cancer.

Increased risk of fundic gland polyps during long‐term proton pump inhibitor therapy

H. Boezen, H. Boezen, S. de Jong, 2006, Alimentary pharmacology & therapeutics.

Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates.

H. Hollema, S. de Jong, A. Karrenbeld, 2003, Scandinavian journal of gastroenterology.

Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia

H. Boezen, H. Hollema, E. Schuuring, 2003, Journal of clinical pathology.

Effects of an inducible anti‐sense c‐myc gene transfer in a drug‐resistant human small‐cell‐lung‐carcinoma cell line

S. de Jong, N. Mulder, H. Burger, 1997, International journal of cancer.

Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 2009, Clinical Cancer Research.

Options for modulation of drug resistance in ovarian cancer.

H. Arts, E. D. de Vries, S. de Jong, 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Molecular Imaging As a Tool for Drug Development and Trial Design.

E. D. de Vries, S. de Jong, J. Gietema, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5

E. D. de Vries, S. de Jong, B. Pennarun, 2011, BMC Cancer.

A prospective evaluation of the pathogenesis of detrusor instability in women, using electron microscopy and immunohistochemistry

S. de Jong, J. Scurry, M. Carey, 2000, BJU international.

Establishment and characterisation of testicular cancer patient-derived xenograft models for preclinical evaluation of novel therapeutic strategies

K. Kok, S. de Jong, G. Meersma, 2020, Scientific Reports.

Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines

E. D. de Vries, S. de Jong, R. van Weeghel, 2003, British Journal of Cancer.

Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.

E. D. de Vries, D. Spierings, S. de Jong, 2010, International journal of oncology.

Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.

A. V. D. Van Der Zee, E. D. de Vries, S. de Jong, 2012, Critical reviews in oncology/hematology.

Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model

A. V. D. Van Der Zee, E. D. de Vries, S. de Jong, 2012, Clinical Cancer Research.

Cancer-drug induced insulin resistance: innocent bystander or unusual suspect.

E. D. de Vries, S. de Jong, J. Gietema, 2015, Cancer treatment reviews.

Targeting FLIP and Mcl‐1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL

H. Hollema, E. D. de Vries, S. de Jong, 2013, The Journal of pathology.

Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.

S. de Jong, N. Mulder, E. de Vries, 1993, Cancer research.

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

Jacqueline A. Hall, Robert Brown, H. Hollema, 2006, British Journal of Cancer.

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).

S. de Jong, S. Withoff, N. Mulder, 1996, Anticancer research.

Heart Failure Stimulates Tumor Growth by Circulating Factors

Lyanne M. Kieneker, R. D. de Boer, M. Maglione, 2018, Circulation.

Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192

S. de Jong, G. Hospers, E. de Vries, 2020, The Journal of Nuclear Medicine.

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

H. Hollema, A. V. D. Van Der Zee, S. de Jong, 2014, Gynecologic oncology.

Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells.

S. de Jong, J. Wesseling, H. Hoekstra, 2004, International journal of oncology.

Mutual interactions between p53 and growth factors in cancer.

E. D. de Vries, E. Vellenga, S. de Jong, 1998, Anticancer research.

Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and in vivo Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets

R. Fehrmann, S. de Jong, G. V. van Dam, 2017, Theranostics.

Evaluation of p16/Ki-67 dual stain cytology performed on self-collected vaginal and clinician-collected cervical specimens for the detection of cervical pre-cancer.

J. Kaldor, S. de Jong, A. Vallely, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines

S. de Jong, M. Walvoort, R. Fehrmann, 2021, Cancer & metabolism.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

R. Bernards, T. Severson, A. V. D. Van Der Zee, 2018, Oncogene.

A New Perspective on Transcriptional System Regulation (TSR): Towards TSR Profiling

Willem A. Kamps, Elisabeth G. E. de Vries, Rudolf S. N. Fehrmann, 2008, PloS one.

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL

H. Hollema, E. D. de Vries, S. de Jong, 2013, British Journal of Cancer.

Modulation of death receptor pathways in oncology.

E. D. de Vries, D. Spierings, S. de Jong, 2003, Drugs of today.

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

R. Bernards, M. Carey, R. Beijersbergen, 2022, Molecular cancer therapeutics.

Reply: The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer

H. Hollema, A. Crijns, S. de Jong, 2007, British Journal of Cancer.

ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells

E. D. de Vries, S. de Jong, C. Gerdes, 2017, Oncotarget.

Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction.

H. Hollema, E. D. de Vries, S. de Jong, 2005, European journal of cancer.

Consequences of chemoresistance for the herpes simplex virus thymidine kinase/ganciclovir-induced bystander effect in a human small cell lung cancer cell line model.

S. de Jong, W. Vaalburg, G. Hospers, 2005, Anticancer research.

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

S. de Jong, T. van der Sluis, E. Bridges, 2023, Journal of Experimental & Clinical Cancer Research.

Antibody-free LC-MS/MS quantification of rhTRAIL in human and mouse serum.

S. de Jong, R. Bischoff, W. Quax, 2013, Analytical chemistry.

Total Abdominal 18F-FDG Uptake Reflects Intestinal Adenoma Burden in Apc Mutant Mice

S. de Jong, E. de Vries, J. Kleibeuker, 2011, The Journal of Nuclear Medicine.

89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

E. D. de Vries, S. de Jong, M. L. Lub-de Hooge, 2017, mAbs.

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Hans Clevers, Manuel Hidalgo, Eva Budinská, 2017, Nature Reviews Cancer.

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Steven B. Neuhauser, Yvonne A. Evrard, Michael W. Lloyd, 2019, Nature Genetics.

Effect of novobiocin on cisplatin cytotoxicity and dna interstrand cross‐link formation in a cisplatin‐resistant, small‐cell lung carcinoma cell line

S. de Jong, N. Mulder, E. D. de Vries, 1993, International journal of cancer.

Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.

S. de Jong, G. Wisman, N. Alkema, 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer

H. Hollema, S. de Jong, H. Klip, 2015, Clinical Cancer Research.

Correspondence re: C. G. Ferreira et al., Apoptosis: target of cancer therapy. Clin. Cancer Res., 8: 2024-2034, 2002.

Elisabeth G E de Vries, E. D. de Vries, S. de Jong, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

S. de Jong, T. van der Sluis, E. Bridges, 2023, Journal of Experimental & Clinical Cancer Research.

Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

S. de Jong, T. van der Sluis, E. Bridges, 2023, Journal of experimental & clinical cancer research : CR.

Interrogating open issues in cancer precision medicine with patient-derived xenografts

C. Caldas, O. Rueda, M. Hidalgo, 2017, Nature Reviews Cancer.

Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53.

S. Sleijfer, S. de Jong, S. Withoff, 1999, Journal of immunotherapy.